Does Centessa Pharmaceuticals (NASDAQ:CNTA) Have A Healthy Balance Sheet?

Simply Wall StMar 17 12:13 ET

Centessa Pharmaceuticals: A Compelling Buy With Promising Orexin Portfolio and Significant Upside Potential

TipRanksMar 17 02:15 ET

Express News | Centessa Pharmaceuticals PLC : Leerink Partners Raises Target Price to $36 From $24

ReutersMar 14 07:35 ET

Centessa Pharmaceuticals Coverage Assumed by Morgan Stanley at Overweight

Dow JonesMar 7 12:24 ET

Morgan Stanley Initiates Centessa Pharmaceuticals(CNTA.US) With Buy Rating, Announces Target Price $27

Moomoo NewsMar 7 09:31 ET · Ratings

Centessa Pharmaceuticals Announces Poster Presentation of Phase 1 Clinical Data for ORX750, a Novel Orexin Receptor 2 (OX2R) Agonist, at the American Academy of Neurology (AAN) 2025 Annual Meeting

GlobeNewswireMar 6 16:14 ET